 |
|
|
|
|
Washington Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2022 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Cancer Targeted Technology
| | | | | Year Established: | 2005 | | Main Contact: | Beatrice Langton-Webster, Ph.D., CEO & Director | | | | Other Contacts: | John Dugan, Founder & Director
Clifford Berkman, Ph.D., CSO, Founder & Director
| | | | Company Description | Cancer Targeted Technology (CTT) is a biotechnology company commercializing unique small molecule inhibitors to pivotal enzyme targets in cancer.
The company's first product, CTT-54, recognizes the molecular target, Prostate Specific Membrane Antigen, with unique and unexploited binding characteristics. PSMA is an exceptional FDA-approved biomarker for prostate cancer and is expressed on close to 100% of prostate tumors with increase in expression correlated with disease progression and low expression in normal tissue. PSMA is also expressed on the new blood vessels of a variety of non-prostatic solid malignancies, making the utility and broader market for CTT-54, significant. | |
|
|
|
|
|
|
|
